A roundup of the latest news and updates for patients with acute myeloid leukemia from CURE®.
There have been several updates in the field of acute myeloid leukemia (AML) over the last several weeks. Here, CURE® looks back at some of the latest news and updates affecting patients with that cancer type.
“If this data is positive, then (eprenetapopt) will be approved and this will be the standard of care for patients with (TP53-mutant myelodysplastic syndrome),” said Dr. Guillermo Garcia-Manero in an interview with CURE® where he discussed the phase 3 trial currently investigating eprenetapopt plus Vidaza (azacytidine) in this patient population.
A health-related quality of life assessment tool, known as Functional Assessment of Cancer Therapy—Leukemia (FACT-Leu), provided a viable and valid outcome measure for patients with AML who are not eligible for intensive therapy.
The Food and Drug Administration (FDA) has granted a fast track designation to BST-236 (aspacytarabine) to treat adults aged 75 years or older with AML, or who have comorbidities that prevent the use of intensive induction chemotherapy.
Researchers have found the combination of Tibsovo (ivosenidib) plus Venclexta (venetoclax) — with or without Vidaza (azacytidine) – to be safe and effective in the treatment of patients with IDH1-mutated acute myeloid leukemia (AML), according to the results of a recent trial presented at the 2020 ASCO Virtual Scientific Program.
The FDA extended the indication of Mylotarg (gemtuzumab ozogamicin) to include the treatment of children aged one month or older with newly diagnosed CD33-positive AML.
